<DOC>
	<DOCNO>NCT00502528</DOCNO>
	<brief_summary>Background Objective : Acute coronary syndrome characterize compromised blood flow epicardial microvascular level . The aim present study investigate effect ET-receptor blockade BQ-123 myocardial perfusion infarct size adjunct PCI-reperfusion therapy patient STEMI . Patients randomize receive periinterventional intravenous BQ-123 placebo .</brief_summary>
	<brief_title>Endothelin Receptor Blockade Acute ST-elevation Myocardial Infarction</brief_title>
	<detailed_description>Background Objective : Acute coronary syndrome characterize compromised blood flow epicardial microvascular level . We previously show thrombectomy ST-elevation myocardial infarction ( STEMI ) accelerate ST-segment resolution , possibly prevent distal embolization . Therefore , analyze vasoconstrictor concentration acute coronary thrombus , find high concentration endothelin ( ET ) correlate magnitude ST-segment resolution within one hour percutaneous coronary intervention ( PCI ) . Furthermore , ET-receptor blockade tezosentan significantly repress vasoconstriction in-vitro model use porcine coronary artery ring incubate coronary thrombus homogenate extract STEMI patient . The aim present study investigate effect ET-receptor blockade BQ-123 myocardial perfusion infarct size adjunct PCI-reperfusion therapy patient STEMI . Methods : Fifty eligible patient randomize receive periinterventional intravenous BQ-123 placebo . The primary endpoint study microvascular function evaluate cardiac magnetic resonance tomography .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>cyclo ( Trp-Asp-Pro-Val-Leu )</mesh_term>
	<criteria>STEMI patient ( define : Evidence ischemic chest pain &gt; 30 minute within &lt; 12 hour new STsegment elevation â‰¥2 mm two contiguous electrocardiographic lead case true posterior infarction reciprocal STsegment depression V1 V2 &gt; 1mm and/or elevate serum creatine phosphokinase twofold elevation troponinT ) , age 18 year , undergo primary percutaneous revascularization ( PCI ) confirm initial TIMI 0 1 infarct relate coronary artery . Significant liver disease Thrombolytic therapy History prior myocardial infarction Current atrial fibrillation History congestive heart failure History migraine headache Significant valvular heart disease , primary myocardial disease Cardiogenic shock ( sRR &lt; 90mmHg need inotropic support ) Childbearing potential Inability read , understand sign inform consent Life expectancy &lt; 3y Prior organ transplantation Medication konazoles , ritonavir , rifampicin sulfonylurea derivative Participation another clinical study Metal implant contraindicate CMR</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Infarction</keyword>
	<keyword>Endothelin</keyword>
	<keyword>Perfusion</keyword>
</DOC>